273 related articles for article (PubMed ID: 18511159)
1. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D
Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159
[TBL] [Abstract][Full Text] [Related]
2. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
3. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.
Thérien A; Bédard M; Carignan D; Rioux G; Gauthier-Landry L; Laliberté-Gagné MÈ; Bolduc M; Savard P; Leclerc D
J Nanobiotechnology; 2017 Jul; 15(1):54. PubMed ID: 28720097
[TBL] [Abstract][Full Text] [Related]
4. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
5. Characterization of immunity induced by M2e of influenza virus.
Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
[TBL] [Abstract][Full Text] [Related]
6. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
7. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
8. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.
Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG
Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564
[TBL] [Abstract][Full Text] [Related]
10. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
11. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
12. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors.
Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonosoff GP; Ravin NV
BMC Biotechnol; 2015 May; 15():42. PubMed ID: 26022390
[TBL] [Abstract][Full Text] [Related]
13. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.
Wu F; Yuan XY; Li J; Chen YH
Vaccine; 2009 Jul; 27(32):4320-4. PubMed ID: 19410621
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].
Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D
Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774
[TBL] [Abstract][Full Text] [Related]
15. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses.
Bolduc M; Baz M; Laliberté-Gagné MÈ; Carignan D; Garneau C; Russel A; Boivin G; Savard P; Leclerc D
Nanomedicine; 2018 Nov; 14(8):2563-2574. PubMed ID: 30193813
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
[TBL] [Abstract][Full Text] [Related]
17. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP.
Babin C; Majeau N; Leclerc D
J Nanobiotechnology; 2013 Apr; 11():10. PubMed ID: 23556511
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
[TBL] [Abstract][Full Text] [Related]
19. A novel M2e based flu vaccine formulation for dogs.
Leclerc D; Rivest M; Babin C; López-Macias C; Savard P
PLoS One; 2013; 8(10):e77084. PubMed ID: 24098576
[TBL] [Abstract][Full Text] [Related]
20. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
